Key Drivers
- Strong Liquidity
- Margin Pressure
- Rich Valuation
AIAI Summary
SDGR should now be viewed primarily as a software-platform execution story, where the key question is whether strong software/ACV growth can outpace shrinking drug-discovery revenue and persistent cash burn before dilution erodes the upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Margin Pressure
- •Rich Valuation
SDGR has strong liquidity, moderate leverage, and healthy gross margins, but persistent operating losses, negative quarterly cash flow, and a still-rich valuation make it a turnaround story rather than a profitable one.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Nearby support
- •Breakout unconfirmed
Over the last month, SDGR has trended higher with higher lows and now sits just below $17.39 resistance, but the recent pullback shows the breakout is unconfirmed unless it holds $15.8-$16.0 support.
Sharp fade from $17.39 into the $16s signals elevated volatility
Sentiment & News
Key News Insights:
- •Hiring Activity
- •Share Weakness
- •AI Theme
Schrödinger is still hiring and drawing AI-drug-discovery attention, but the stock recently sold off and remains below estimated value.
The headlines are mildly negative for near-term sentiment but keep Schrödinger on watch as an AI-enabled biotech name
Similar Companies in Healthcare
Other companies in the same sector with AI ratings